IKTライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (27 4月 2024 @ 05:00):

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain...

Stats
本日の出来高	98 979.00
平均出来高	103 828
時価総額	11.08M
EPS	$0 ( 2024-03-29 )
次の収益日	( $-0.790 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.480
ATR14	$0.0210 (1.23%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Werner Milton H.	Buy	45 000	Stock Option (right to buy)
2024-04-01	Lees-rolfe Garth	Buy	90 000	Stock Option (right to buy)
2024-04-01	Lees-rolfe Garth	Sell	5 834	Stock Option (right to buy)
2023-06-30	Berman Dennis N	Buy	6 667	Stock Option (right to buy)
2023-06-30	Dion Gisele	Buy	6 667	Stock Option (right to buy)

INSIDER POWER
96.54
Last 62 transactions
Buy: 1 923 769 \| Sell: 2 120 717

ボリューム相関

長: -0.10 (neutral)

短: 0.12 (neutral)

Signal:(46.584) Neutral

Inhibikase Therapeutics, 相関

10 最も正の相関
SVOK	0.82

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Inhibikase Therapeutics, 相関 - 通貨/商品

0.36
( neutral )

0.08
( neutral )

0.00
( neutral )

0.60
( weak )

-0.28
( neutral )

-0.15
( neutral )

Inhibikase Therapeutics, 財務諸表

Annual	2023
収益:	$260 500
総利益:	$83 102.00 (31.90 %)
EPS:	$-3.57

FY	2023
収益:	$260 500
総利益:	$83 102.00 (31.90 %)
EPS:	$-3.57

FY	2022
収益:	$123 440
総利益:	$116 717 (94.55 %)
EPS:	$-4.26

FY	2021
収益:	$3.10M
総利益:	$3.10M (100.00 %)
EPS:	$-0.810

Financial Reports:

No articles found.

Inhibikase Therapeutics,

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.